Evidence map›Paper›PMID 31915847›Full record

Trial reportEuropean journal of clinical pharmacology2020

Intake of aspirin prior to metamizole does not completely prevent high on treatment platelet reactivity.

Christian Pfrepper, Carolin Dietze, Yvonne Remane, Thilo Bertsche, Susanne Schiek, Thorsten Kaiser, Ines Gockel, Christoph Josten, Sirak Petros

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in European journal of clinical pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Christian PfrepperDivision of Haemostaseology, Medical Department I, University Hospital Leipzig, Leipzig, Germany. Christian.pfrepper@medizin.uni-leipzig.de.ORCID http://orcid.org/0000-0002-0485-7402
Carolin DietzeHospital Pharmacy, University Hospital Leipzig, Leipzig, Germany.
Yvonne RemaneHospital Pharmacy, University Hospital Leipzig, Leipzig, Germany.
Thilo BertscheDrug Safety Center and Department of Clinical Pharmacy, Leipzig University, Leipzig, Germany.
Susanne SchiekDrug Safety Center and Department of Clinical Pharmacy, Leipzig University, Leipzig, Germany.
Thorsten KaiserInstitute of Laboratory Medicine, University Hospital Leipzig, Leipzig, Germany.
Ines GockelDepartment of Visceral, Transplantation, Thoracic and Vascular Surgery, University Hospital Leipzig, Leipzig, Germany.
Christoph JostenDepartment of Orthopaedics, Trauma and Plastic Surgery, University Hospital Leipzig, Leipzig, Germany.
Sirak PetrosDivision of Haemostaseology, Medical Department I, University Hospital Leipzig, Leipzig, Germany.
University Hospital Leipzig · DELeipzig University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMetamizole can sterically inhibit aspirin (ASA) from binding to cyclooxygenase 1 (COX1). It is recommended that ASA should be taken 30 min prior to metamizole to maintain the irreversible inhibition of arachidonic acid (AA)-induced platelet aggregation. We aimed to analyse the inhibitory effect of ASA and metamizole on AA-induced platelet aggregation over the course of the day.

methodsWe analysed hospitalized patients who ingested ASA at least 30 min prior to metamizole (recommended dosing group, n = 15), metamizole prior or simultaneously with ASA (not recommended dosing group, n = 16) and patients with unknown or mixed intake (mixed dosing group, n = 5). AA-induced light transmission (LTA) and impedance aggregometry (IA) were measured before, 1-2 and 5-6 h after the intake of ASA ± metamizole.

resultsMaximum AA-induced LTA prior to the intake of ASA was significantly lower and the rate of high on treatment platelet reactivity (HTPR) higher in the recommended compared with the not recommended dosing group (19.6% vs. 46.9%, p = 0.011 and 4/15 vs. 12/16 patients, p = 0.017). There was no difference when IA was used. Maximum AA-induced LTA after the intake of ASA ± metamizole was lower in patients in the not recommended but not in the recommended dosing group. All patients with HTPR in the recommended dosing group had regular inhibition of AA-induced LTA after discontinuation of metamizole.

conclusionCo-medication of ASA and metamizole significantly influences platelet inhibition with variations during the day and can cause HTPR in patients taking ASA prior to metamizole or simultaneously.

Indexed as

Administration, OralAgedAnti-Inflammatory Agents, Non-SteroidalAspirinCardiovascular DiseasesDipyroneDrug Administration ScheduleDrug InteractionsFemaleHumansMaleMiddle AgedPlatelet AggregationPlatelet Aggregation InhibitorsAnti-Inflammatory Agents, Non-SteroidalAspirinDipyronePlatelet Aggregation InhibitorsAspirinDipyroneDrug interactionsMetamizolePlatelet aggregationSurgery

Identifiers

PMID31915847
OpenAlexW2998769871

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.